LENZ Therapeutics (LENZ) Operating Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Operating Expenses data on file, last reported at $46.0 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $46.0 million, up 171.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $139.3 million (up 134.35% YoY), and the FY2025 annual result was $110.2 million, up 88.07% from the prior year.
• Operating Expenses advanced to $46.0 million in Q1 2026 per LENZ's latest filing, from $40.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $46.0 million in Q1 2026 and troughed at $12.6 million in Q1 2023.
• A 5-year average of $23.1 million and a median of $21.9 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 177.09% in 2022, then slumped 51.4% in 2023.
• A 5-year view of Operating Expenses shows it stood at $26.8 million in 2022, then fell by 6.59% to $25.0 million in 2023, then tumbled by 39.07% to $15.2 million in 2024, then soared by 163.06% to $40.1 million in 2025, then advanced by 14.94% to $46.0 million in 2026.
• Business Quant data shows LENZ's Operating Expenses at $46.0 million in Q1 2026, $40.1 million in Q4 2025, and $31.4 million in Q3 2025.